期刊文献+

牛血清白蛋白荧光猝灭测定药物中的头孢孟多酯

Determination of Cefamandole in Drug by Bovine Serum Albumin Fluorescence Quenching Method
下载PDF
导出
摘要 应用牛血清白蛋白(BSA)荧光猝灭法建立了一种测定药物中头孢孟多酯(CEF)含量的新方法。牛血清白蛋白具有很强的内源荧光性,而头孢孟多酯溶液本身不产生荧光。当头孢孟多酯与BSA结合后,会导致其荧光强度下降。牛血清蛋白在λex=340 nm处的荧光猝灭程度与头孢孟多酯的量在一定浓度范围内呈良好的线性关系,据此建立测定药品中头孢孟多酯含量的新方法。该结合物的最大发射波长为λmax=340 nm,与头孢孟多酯物质的量浓度在2.18×10^-6~2.62×10^-5 mol·L-1范围内线性关系良好。其线性回归方程为ΔF=2.42×10^7CCEF-35.155,相关系数r=0.996 9,检出限为8.582 58×10-7 mol·L-1,RSD为0.16%,加标回收率为94.67%~98.43%。本方法操作简便、快速,用于实际样本的测定,结果满意。 A new method to detect the cefamandole in drug by fluorescence quenching of bovine serum albumin(BSA)was investigated. The BSA had a strong intrinsic fluorescence because of tryptophan and tyrosine,and cefamandole(CEF) solution itself didn′t produce fluorescence,but when cefamandole combined with the BSA,the fluorescence intensity of BSA was decreased.Based on in a certain range, the fluorescence quenching of BSA in the λex = 340 nm having a good linear relationship with the concentration of cefamandole, a new method to detect the cefamandole in drug was established. The conjugate of BSA and cefamandole had a max fluorescence value at 340 nm which was found the decreased intensity of fluorescence at 340 nm was proportion to cefamandole in the range of 2.18×10^- 6~2.62×10^- 5mol·L- 1. The linear regression equation was ΔF=2.42×10^7CCEF- 35.155 with a correlation coefficient of 0.996 9. The detection limit was 1.029 91×10- 6mol·L- 1,the relative standard deviation was 0.16% and the average recovery of sample was 94.67%~98.43%.The method was simple and rapid,and could be applied to detect the trace cefamandole in drug with satisfactory results.
作者 李红霞 刘里
出处 《煤炭与化工》 CAS 2014年第9期65-67,119,共4页 Coal and Chemical Industry
基金 曲靖师范学院实验教学研究项目(综合性 设计性实验)(Syjx2013010)
关键词 头孢孟多酯 荧光猝灭 牛血清白蛋白 cefamandole fluorescence quenching bovine serum albumin
  • 相关文献

参考文献4

二级参考文献15

  • 1肖涛,张孝清,曹芳,田春梅,王锦堂.头孢丙烯的合成[J].中国医药工业杂志,2004,35(7):388-390. 被引量:13
  • 2张明发.头孢丙烯的抗菌药理与临床[J].上海医药,2005,26(3):111-117. 被引量:33
  • 3刘新宇,吴芳.头孢丙烯在下呼吸道细菌感染患者的药代动力学研究[J].药学实践杂志,2006,24(3):144-146. 被引量:5
  • 4Barriere SI.. Review of in vitro activity, pharmacokinetic char acteristics,safety and efficacy of cefproil, a new oral eephalo sporin[J]. Ann harmacother, 1993,27:1082-1089.
  • 5Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infeetions[J]. Drugs, 2004,64:1433-1464.
  • 6Wiseman LR,Benfield P. Cefprozil,A review of its antibaeteri al activity, pharmacokinetic properties, and therapeutic potential[J]. Drugs, 1993,45 (2) :295.
  • 7Park TH, Kim JK, Jee JP, et al .HPLC method for simultaneous determination of cefprozil diastereomers in human plasma [J] .J Pharm Biomed Anal, 2004, 36 (1):243.
  • 8LI Xiao-li, NI Mei-yuan, WANG Benojie, et al. Pharmacokinetics and Bioequivalence of Cefprozil Granules and Cefprozil Tablets inHeatlthChinese Volunteers [ J ]. Journal of Chinese Pharmaceutical Sciences. 2006,15 (4) :243-247.
  • 9Wen Chyi Shyu, Umesh A. Shukla, Vinod R. Shah, ctal. Simutaneous High-Performance Liquid Chromatographic Analysis of Cefprozil Diastereomers in a Pharmacokinetic Study [ J ]. Pharmaceutical Reserch, 1991,8(8) :9920-996.
  • 10国家食品药品监督管理局.化学药物制剂人体生物利用度和生物等效性研究技术指导原则[S].2005.3

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部